$ Range

2

Click here to load reader

Transcript of $ Range

Page 1: $ Range

$ Range<200

200-399400-599600-799

>800

Cost Code<***********

AntifungalsCost per day of IV therapy ( * )

amphotericin b deoxycholate <*abelcet - amphotericin b lipid complex≠ ***Ambisome - amphotericin b liposomal § ****caspofungin≠ *fluconazole <*micafungin § *voriconazole ≠ *(*) Cost based on most common daily dose for 80kg adult pt≠ Guideline or restricted use applies§ Non-formulary

OHSU Formulary At-a-GlanceAminoglycosidesamikacingentamicinkanamycintobramycin

Penicillinsamoxicillinampicillinpenicillin G benzathinepencillin G sodiumpenicllin G potassiumAntistaphylococcaldicloxacillinnafcillinoxacillinExtended Spectrumamoxicillin/clavulanateampicillin/sulbactampiperacillin/tazobactampiperacillinticarcillin/clavulanate

Cephalosporins1st Generationcefazolincephalexin2nd Generationcefotetancefuroxime3rd Generationcefdinircefotaxime ≠ cefpodoximeceftazidimeceftriaxone ≠ 4th Generationcefepime ≠

OHSU 2005 Anti-infective Pocket Card

A gift from the Department of Pharmacy Services

Carbapenemsertapenem≠ imipenem/cilastatin≠ meropenem≠

Fluroquinolonesciprofloxacinmoxifloxacin≠

Macrolidesazithromycinclarithromycinerythromycinerythromycin /sulfisoxazole

Tetracyclinesdemeclocyclinedoxycyclineminocyclinetetracyclinetigecycline ≠

Miscellaneous Antibioticsaztreonamchloramphenicolclindamycindaptomycin≠ linezolid≠ metronidazolenitrofurantoinquinupristin/dalfopristin≠ rifampintrimethoprimtrimethoprim/sulfamethoxvancomycin≠

≠ Guideline or restricted use applies, refer to the online formulary for details. Direct formulary questions to OHSU Drug Information Service, 503-494-7530, [email protected], M-F 0830-1630

Antimycobacterialscycloserineethambutolisoniazidpyrazinamiderifabutinrifampin/isoniazidrifampin

Antifungalsamphotericin b deoxycholateamphotericin b lipid complex ≠ caspofungin≠ fluconazoleflucytosinegriseofulvinitraconazoleketoconazolenystatinvoriconazole ≠

Antiviralsacycloviramantadinecidofovirfamciclovirfoscarnetgancicloviroseltamivirribavirinvalacyclovir≠ valganciclovir

≠ Guideline or restricted use applies, refer to the online formulary for details. Direct formulary questions to OHSU Drug Information Service, 503-494-7530, [email protected], M-F 0830-1630

OHSU Formulary At-a-Glance

Page 2: $ Range

OHSU Antibiogram 2005ALL SOURCES ISOLATES

(Percent Susceptibilities of the Most Common Pathogens)

Cost per day of Antibiotics IV therapy ( * )

amikacin 100 98 100 100 97 100 99 99 100 97 - - - - - - - - ampicillin/sulbactam $$ampicillin 58 0 0 0 0 2 0 0 86 - - 0 88 - - - - - azithromycin $ampicillin/sulbactam 67α 1 100 78 88 0 6 0 97 - - 100 - 56 0 99 27 - cefazolin <$aztreonam 98 80 100 90 97 85 76 98 99 62 - 8 - - - - - - cefepime≠ <$cefazolin 91 0 100 61 93 0 0 0 91 - - 0 - 56 0 100 27 - cefotaxime≠ $cefepime (restricted) 99 99 100 100 97 100 99 100 100 87 - 83 - - - - - - cefotetan $$cefotetan 99 4 100 100 98 0 7 100 99 - - 0 - - - - - - ceftazidime $$$ceftazidime 98 78 100 100 96 84 73 98 100 78 39 59 - - - - - - ceftriaxone≠ $ceftriaxone (restricted dose) 98 76 100 99 97 85 74 100 100 0 - 0 - - - - - 99 cefuroxime $$cefuroxime 90 73 91 81 89 66 26 0 94 - - 0 - - - - - - ciprofloxacin $$ciprofloxacin 91 92 100 100 94 97 96 90 90 72 22 68 - - - - - - clindamycin $clindamycin - - - - - - - - - - - - - 75 59 87 59 - daptomycin≠ $$$$$erythromycin - - - - - - - - - - - - 18 46 8 75 32 84 gentamicin <$gentamicin 94 86 100 100 96 100 96 98 97 86 - 95 - - - - - - imipenem/cilastatin≠ $$$$$imipenem/cilastatin (restricted) 100 100 100 98 99 100 100 99 - 86 - 98 - - - - - - linezolid≠ $$$$$levofloxacin (non-formulary) 91 94 100 100 97 100 98 96 94 73 82 71 75 63 22 95 48 100 meropenem≠ $$linezolid (restricted) - - - - - - - - - - - - 98 100 99 100 100 100 metronidazole $$meropenem (restricted) - - - - - - - - - 85 - - - - - - - - moxifloxacin≠ $nitrofurantoin 97 90 93 86 23 19 35 0 0 - - 0 88 100 100 100 100 - nafcillin $$$$$oxacillin (for nafcillin similar expected) - - - - - - - - - - - - - 56 0 100 27 - penicillin G $$$penicillin - - - - - - - - - - - - 86 0 0 1 1 82 piperacillin/tazobactam $$$piperacillin/tazobactam 99 87 100 82 95 84 83 95 100 92 - 74 - - - - - - tobramycin <$quinupristin/dalfopristin (restricted) - - - - - - - - - - - - 19 100 100 100 99 - vancomycin≠ $$rifampin - - - - - - - - - - - - - 99 98 100 93 - (*) Based on most common daily adult dosetetracycline 77 - - - - - - - - - - - 27 94 91 96 85 91 ≠ Guideline or restricted use appliesticarcillin/clavulanate - - 100 - 93 - 70 - - 73 26 - - - - - - -tobramycin 94 88 100 100 96 100 95 87 98 95 - 84 - - - - - -trimethoprim/sulfamethoxazole 79 78 98 94 93 98 91 99 90 0 86 76 - 99 99 99 - 82vancomycin (guideline use) - - - - - - - - - - - - 97 100 100 100 100 100

α Amoxicillin/clavulanate sensitivity to E. coli = 90% € Streptococcus pneumoniae data includes both OHSU and Kaiser data

GM POS. AEROBESOTHER BACILLI COCCI

GM NEG. AEROBESENTERIC BACILLI

Kle

bsie

lla p

neum

onia

e (4

00)

Ent

erob

acte

r aer

ogen

es (6

0)

Ste

notro

phom

onas

mal

toph

ilia

(80)

Ent

erob

acte

r clo

acae

(200

)

Ser

ratia

mar

cesc

ens

(110

)

Pro

teus

mira

bilis

(125

)

Pse

udom

onas

aer

ugin

osa

(615

)

$ Range<20

20-3940-5960-7980-99>100

Cost Code<$$$$

$$$$$$$

$$$$$

Aci

neto

bact

er b

aum

anni

i (80

)

Ent

eroc

occu

s sp

. (59

0)

Sta

phyl

ococ

cus

aure

us (2

015)

Coa

g ne

gativ

e S

taph

yloc

occu

s (7

25)

Stre

ptoc

occu

s pn

eum

onia

e (1

30)€

MR

SA (M

ethi

cilli

n-re

sist

ant S

.aur

eus)

(880

)

MS

SA

(met

hici

llin-s

usce

ptib

le S

.aur

eus)

(113

5)

Questions?Lab Central: 503-494-7383

Drug Information Service:503-494-7530, [email protected] 0830 - 1630

web version + resistance tracking:www.ohsu.edu/pharmacy

Esc

heric

hia

coli

(198

0)

Citr

obac

ter f

reun

dii (

85)

Kle

bsie

lla o

xyto

ca (1

05)

Citr

obac

ter k

oser

i (45

)

Prepared by OHSU Drug Information/Drug Policy Service, Dept of Pharmacy Services with data provided by OHSU Clinical Microbiology Laboratories 1/2006